URL Pharma has acquired a 19,000 sq ft facility equipped for development and manufacture of modified release products from PharmPro.
The facility includes fluid bed technology, which is used in the water and solvent coating processes that are needed in the development and manufacture of modified release products.
Furthermore, the acquisition includes DuraGran. This is a proprietary technology platform enables the production of uniform, small granules, which are also used in modified release products.
URL will also acquire the services of 17 former PharmPro employees that have critical engineering expertise. These employees, infrastructure and technology have been acquired to improve URL’s in-house capabilities.